Piramal Buys Bayer’s Imaging Portfolio

In a deal that could propel the $650-million Piramal Healthcare into the billion dollar revenue league, the Ajay Piramal-led company has bought the molecular imaging research and development portfolio of Bayer AG, which includes the rights to an Alzheimer’s treatment drug.
Hindustan Times